CD22-Targeted CAR T-Cell Therapy Active for Relapsed/Refractory ALL

T-cell therapy targeting CD22, a protein found on the surface of leukemic cells, was safe and feasible in a small and ongoing study of patients with ALL.

Source: CancerNetwork - December 5, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASH 2016 Hematologic Malignancies Leukemia & Lymphoma News Source Type: news